,17 IFN-α kinoid vaccination induces antibodies that cross-neutralize all IFNα subtypes, which in ∼50% of immunized SLE patients has shown therapeutic efficacy.18 This evidence concerns the gene IFNA1 and systemic lupus erythematosus.